Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Giant Biogene IPO: Peer Comparison and Valuation

Giant Biogene: Thoughts on First Day Trading

Does Meituan Have the Appetite to Serve HK Food Delivery Market and Take On Foodpanda and Deliveroo?

Tencent Seeks Majority Stake in Overseas Game Companies as Game Revenue Slows Down Further

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/giant-biogene-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:35950:1" rel="noopener">Giant Biogene Holding (GBH HK)</a> designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient in China.</li>
<li>The company has filed for an IPO on the Hong Kong Stock Exchange and plans to raise proceeds of around HK$500m.</li>
<li>We remain positive on Biogene’s growth prospects as it operates in a growing market which should further benefit from regulatory tailwinds.</li>
</ul>



Giant Biogene Holding (GBH HK) designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient in China.
The company has filed for an IPO on the Hong Kong Stock Exchange and plans to raise proceeds of around HK$500m.
We remain positive on Biogene’s growth prospects as it operates in a growing market which should further benefit from regulatory tailwinds.


Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns